Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 69Carcinoma, Non-Small-Cell Lung 62Stomach Neoplasms 32Prostatic Neoplasms 21Nasopharyngeal Carcinoma 20Lung Neoplasms 20Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Neoplasm Metastasis 8Head and Neck Neoplasms 7Inflammatory Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5HER2-positive Breast Cancer 5Adenocarcinoma 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4NSCLC 4Carcinoma, Squamous Cell 4Sarcoma 3Nasopharyngeal Neoplasms 3Hypopharyngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Ovarian Epithelial 3Breast Diseases 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tongue Neoplasms 2Squamous Cell Lung Cancer 2

Interventions

pamiparib 1fludarabine 1Single Photon Emission Computed Tomography Computed Tomography 1Selegiline 1Docetaxel 1Cyclophosphamide 1177Lu-EB-PSMA-617 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Metastatic Castration-resistant Prostate Cancer × Docetaxel × Clear all
NCT04586543 2020-10-14

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

University of Pecs

Phase 2 Unknown
110 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡